Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel.

ABSTRACT: Prostate cancer (PCa) that progresses after androgen deprivation therapy (ADT) remains incurable. The underlying mechanisms that account for the ultimate emergence of resistance to ADT, progressing to castrate-resistant prostate cancer (CRPC), include those that reactivate androgen receptor (AR), or those that are entirely independent or cooperate with androgen signaling to underlie PCa progression. The intricacy of metabolic pathways associated with PCa progression spurred us to develop a metabolism-centric analysis to assess the metabolic shift occurring in PCa that progresses with low AR expression. We used PCa patient-derived xenografts (PDXs) to assess the metabolic changes after castration of tumor-bearing mice and subsequently confirmed main findings in human donor tumor that progre

SUBMITTER: Labanca E 

PROVIDER: S-EPMC8566229 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature